or other adverse events when they used or stopped using Truvada for HIV pre-exposure prophylaxis (PrEP), according to an analysis from the iPrEx study presented at the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last month in
Vancouver, Canada. This is a potential concern because the drugs in Truvada – tenofovir and emtricitabine – are active against HBV as well as HIV.